Immix Biopharma Investor Presentation Deck

NXC-201 Clinical Development Plan Through FDA BLA Submissions Expansion Into Additional Sites in the U.S. Planned for Q4 2023/01 2024 Target Indication Relapsed/refractory AL Amyloidosis NXC-201 Select Autoimmune Indications NXC-201 BCMA-exposed multiple myeloma NXC-201 Phase 1b/2a NXC-201 Ongoing: NEXICART-1 (NCT04720313) U.S. IND Approved Phase 1b/2a NXC-201 Ongoing: NEXICART-1 (NCT04720313) Phase 2a Open Label, Potentially Pivotal Trial Trial Proof-of-concept clinical data to be generated in 2nd line therapy Relapsed/refractory Light Chain (AL) Amyloidosis >30 Patients Single arm, open label Select Autoimmune Indications Single arm, open label Recommended Phase 2 Dose (RP2D) Already Relapsed/refractory Multiple Myeloma Established at 800 million NXC-201 CAR+T Cells 97 patients At RP2D Single arm, open label Submit to FDA (BLA) Submit to FDA (BLA) Clinical Effectiveness Submit to FDA (BLA) ●●● IMMIX S BIOPHARMA Status -25% Patients Dosed Site Activation -50% Patients Dosed FDA approval precedents include: Abecma/BMS (single arm study 100 patients in efficacy results population, FDA approved 2021); Carvykti/J&J (single arm study 97 patients in efficacy results population, FDA approved 2022); Elrexfio/Pfizer (single arm study 97 patients in efficacy results population, FDA approved 2023) 26

View entire presentation